Clinically relevant studies have demonstrated that NSCLC patients expressing high levels of IL-10 have poor prognosis (23, 24).However, it has also been reported that insufficient expression of IL-10 in tumors is a negative prognostic factor for early-stage NSCLC (21, 25, 26). The gene discussed is IL10; the disease is non-small cell lung carcinoma.